Researchers raise concerns about a new study revealing potential hazards for women using abortion pills

Title: 'Alarming': Pro-Life Advocate Speaks Out on New Study Revealing Dangers of Abortion Pill

Researchers raise concerns about a new study revealing potential hazards for women using abortion pills

In an exclusive chat, SBA Director of Legal Affairs Katie Glenn Daniel shed light on a study exposing an alarming number of severe side effects among women who have taken mifepristone, infamously known as the "abortion pill."

The shocking study, conducted by researchers at the Ethics & Public Policy Center, paints a stark contrast to the claims made by the FDA on the drug label. According to Daniel, "The biggest thing that will shock most readers of this report is just how different the findings in this study are from what the FDA claims on the abortion drug label."

The study revealed that more than one in ten women (11%) encounter severe side effects like infection, hemorrhaging, or life-threatening complications after taking the abortion drugs. This rate is 22 times higher than the one reported on the FDA-approved drug label.

Dr. Christina Francis, a board-certified OB/GYN, expressed her concern, stating, "These reports confirm what physicians like me and our members are seeing in our clinical practice: that abortion drugs pose significant dangers to women."

Mifepristone is a pregnancy-blocking drug often combined with misoprostol to terminate pregnancies. The Biden administration has made efforts to ensure its availability through the mail, contributing to a rise in medication abortions in the U.S.

Katie Glenn Daniel emphasized the potential risks associated with this practice, "You don't even know if a pregnant woman's getting these drugs. There have been cases where men order these drugs, to slip them to somebody... So you really lose a lot of the safeguards that are in place."

Daniel hopes this study will prompt the FDA to take action to safeguard women and unborn children. "A drug that puts one in ten women in the hospital is certainly not a drug that is quote unquote good for women," she said.

The study has grabbed the attention of policymakers, including Representative Riley Moore, who criticized Democrats for pushing dangerous policies.

As the debate on women's health and abortion continues, this study underscores the urgent need for a more open discussion on the safety of abortion medications like mifepristone.

Contributions by Melissa Rudy, our website's dedicated reporter.

Andrew Mark Miller is a reporter at our website. Connect with him on Twitter @andymarkmiller and send tips to [email protected].

Enrichment Data:

Current Evidence on Safety and Side Effects of Mifepristone

A recent study by the Ethics and Public Policy Center analyzed data from over 865,000 mifepristone abortions conducted between 2017 and 2023. The study found that:

• Serious Adverse Effects: The study revealed that approximately 11% of women experience severe adverse effects such as sepsis, infection, and hemorrhaging within 45 days following a mifepristone abortion.
• Comparison to FDA Claims: The real-world rate of serious adverse events is at least 22 times higher than the figure of "less than 0.5%" reported in clinical trials on the drug label. This discrepancy suggests that the FDA's summary may underestimate the actual risks associated with mifepristone.

For more comprehensive insights, visit our website.

1. The alarming study conducted by the Ethics & Public Policy Center on mifepristone, often used for medication abortions, reveals a significant discrepancy between the reported severe side effects and what the FDA claims on the drug label.
2. The study's findings show that more than one in ten women (11%) encounter severe side effects after taking the abortion drugs, which is 22 times higher than the rate reported on the FDA-approved drug label.
3. The study is essential as it sheds light on the real-world safety issues related to mifepristone, a pregnancy-blocking drug, and fuels the ongoing debate about women's health and the dissemination of abortion medications.
4. Notably, the study has caught the attention of policymakers, such as Representative Riley Moore, who have been critical of the perceived risks associated with the Biden administration's efforts to make mifepristone more accessible.
5. As the discussion about the role of science, health, and mental health in policy-and-legislation continues, particularly in relation to women's health matters, it's crucial to approach such matters with an informed opinion and take action to ensure the safety of all parties involved.

Read also: